Release date: 2024-08-09 15:53:40 Article From: Lucius Laos Recommended: 178
Capmatinib is an oral, selective, ATP-competitive c-Met kinase inhibitor that inhibits c-Met kinase for the treatment of metastatic non-small cell lung cancer with mutations in MET exon 14.
With the successful launch of capmatinib in the domestic market and its wide application in clinical practice, doctors and patients should pay close attention to the possible interaction of the drug.
CYP3A inducers may reduce plasma concentrations of capmatinib and weaken antitumor activity. To maintain the efficacy of the drug, it is recommended to avoid concomitant use with these inducers.
Common CYP3A inducers include, but are not limited to, rifampicin, rifapentine, phenytoin, carbamazepine, barbiturates, and St. John's wort.
Simultaneous use of CYP1A2 substrates may lead to an increase in blood concentrations of these substrates, which may trigger serious adverse effects. Concomitant use with CYP1A2 substrate should be avoided as much as possible. Common CYP1A2 substrates include, but are not limited to, caffeine, aflatoxin B1, and paracetamol.
Understanding the dosage requirements of the drug is very important for doctors and patients to develop a drug treatment plan, which is organized according to the drug label as follows:
The recommended dose of capmatinib is 400 mg orally twice daily. Can be taken before or after meals without special adjustments. Tablets should be swallowed whole, not broken, crushed, or chewed. If you miss a dose or vomit after taking the medicine, you don't need to make up the dose, and you can take the next dose as scheduled for your next dose.
The Lucius Pharmaceutical factory covers an area of 25,000 square meters and is equipped with advanced production facilities and equipment. The product line covers anti-tumor drugs, cardiovascular drugs, hematology drugs, diabetes drugs, dermatology drugs, men's health drugs and anti-aging drugs, etc., providing more than 200 generic drug varieties.
The factory strictly abides by the international Good Manufacturing Practice (GMP), strictly controls every link of raw material procurement, production process and finished product inspection, and has a perfect quality traceability system to ensure the controllability and traceability of drug quality.
[Warm tips] Patients should strictly follow the doctor's guidance when using capmatinib and maintain a healthy lifestyle and eating habits, which can help improve the efficacy of the drug and improve overall health.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: